| 1 | Extra-hepatic cancers in metabolic fatty liver syndromes. 2023;11 doi: 10.37349/edd.2023.00014 |
| 2 | Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. 2021; doi: 10.37349/emed.2021.00061 |
| 3 | Precision medicine in nonalcoholic fatty liver disease. 2022;37:1175 doi: 10.1111/jgh.15850 |
| 4 | Towards Multiplexed and Multimodal Biosensor Platforms in Real-Time Monitoring of Metabolic Disorders. 2022;22:5200 doi: 10.3390/s22145200 |
| 5 | Emerging role of aging in the progression of NAFLD to HCC. 2023;84:101833 doi: 10.1016/j.arr.2022.101833 |
Metabolism and Target Organ Damage
